Association of tamoxifen resistance and lipid reprogramming in breast cancer
Association of tamoxifen resistance and lipid reprogramming in breast cancer
About this item
Full title
Author / Creator
Publisher
BioMed Central Ltd
Journal title
Language
English
Formats
Publication information
Publisher
BioMed Central Ltd
Subjects
More information
Scope and Contents
Contents
Tamoxifen treatment of estrogen receptor (ER)-positive breast cancer reduces mortality by 31%. However, over half of advanced ER-positive breast cancers are intrinsically resistant to tamoxifen and about 40% will acquire the resistance during the treatment. In order to explore mechanisms underlying endocrine therapy resistance in breast cancer and...
Alternative Titles
Full title
Association of tamoxifen resistance and lipid reprogramming in breast cancer
Authors, Artists and Contributors
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_gale_infotracmisc_A551665167
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_gale_infotracmisc_A551665167
Other Identifiers
ISSN
1471-2407
E-ISSN
1471-2407
DOI
10.1186/s12885-018-4757-z
